# Phase 3 Pulmonary Disease, Chronic: 32 recruiting (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 32 trials in phase 3 for Pulmonary Disease, Chronic Obstructive that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 3 Pulmonary Disease, Chronic Obstructive trials: 32 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-3/pulmonary-disease-chronic-obstructive

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 32
- Recruiting or not yet: 32
- Read on: November 19, 2026

## Trials

The 25 newest of 32, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2026 | NCT07907991 | The AIRWARD Study: A Study to Test Whether Verducatib Helps People With Chronic Obstructive Pulmonary Disease | Boehringer Ingelheim | Phase 3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 1,800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07907991) |
| October 15, 2026 | NCT07874815 | Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of... | Merck Sharp & Dohme LLC | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 2,136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07874815) |
| September 24, 2026 | NCT07839884 | A Continuation Study of Tilrekimig in Adults With Moderate-to-Severe Long-Term Breathing Difficulty, Known by the Medical Term of Chronic... | Pfizer | Phase 3 | Recruiting | Moderate to Severe Chronic Obstructive Pulmonary Disease | 1,360 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07839884) |
| September 18, 2026 | NCT07828353 | A Clinical Study of REGEND001 for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) | Regend Therapeutics | Phase 3 | Not yet recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 102 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828353) |
| August 21, 2026 | NCT07780669 | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very... | GlaxoSmithKline | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780669) |
| August 21, 2026 | NCT07780656 | A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very... | GlaxoSmithKline | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 624 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780656) |
| June 22, 2026 | NCT07658339 | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of HSK39004 Inhalation Suspension in Patients With COPD | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 387 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07658339) |
| June 8, 2026 | NCT07634367 | Long-Term Safety and Efficacy of HSK39004 Inhalation Suspension in COPD | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634367) |
| May 22, 2026 | NCT07604103 | Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute... | University of Brawijaya | Phase 3 | Recruiting | Acute Coronary Syndromes (ACS), Pneumonia, COPD (Chronic Obstructive Pulmonary Disease) | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07604103) |
| May 13, 2026 | NCT07583849 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase III Study of HSK39004 Inhalation Powder for the Treatment... | Haisco Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | COPD (Chronic Obstructive Pulmonary Disease) | 376 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583849) |
| May 4, 2026 | NCT07566195 | Long-term Safety and Tolerability of Tozorakimab in Patients With COPD and History of Exacerbations | AstraZeneca | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease, COPD | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566195) |
| April 29, 2026 | NCT07555483 | A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With... | Grifols Therapeutics LLC | Phase 3 | Recruiting | Alpha 1 Antitrypsin Deficiency | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07555483) |
| March 11, 2026 | NCT07464587 | Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07464587) |
| January 9, 2026 | NCT07330310 | A Phase 3 Trial of JKN2401 Injection in COPD | Joincare Pharmaceutical Group Industry Co., Ltd | Phase 3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 888 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07330310) |
| September 24, 2025 | NCT07190222 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic... | Sanofi | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease | 942 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190222) |
| September 24, 2025 | NCT07190209 | Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic... | Sanofi | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease | 942 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07190209) |
| September 17, 2025 | NCT07177339 | eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2... | GlaxoSmithKline | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 1,196 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07177339) |
| August 29, 2025 | NCT07147946 | Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 3 | Not yet recruiting | Chronic Obstructive Pulmonary Disease | 666 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07147946) |
| July 2, 2025 | NCT07047092 | Non-invasive Ventilation or CPAP in OSA-COPD Following Admission for an Acute Hypercapnic Respiratory Failure | Assistance Publique - Hôpitaux de Paris | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease Exacerbation, Obstructive Sleep Apnea Exacerbation | 386 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047092) |
| June 26, 2025 | NCT07039669 | Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive (COPD) | 594 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07039669) |
| May 31, 2025 | NCT06999343 | Exploring the Anti-ageing Effects of Metformin in COPD | Fundación Instituto de Investigación Sanitaria de Navarra | Phase 3 | Not yet recruiting | COPD | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06999343) |
| May 7, 2025 | NCT06961214 | Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation... | GlaxoSmithKline | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 961 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06961214) |
| May 6, 2025 | NCT06959095 | Depemokimab as an Extended Treatment Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation | GlaxoSmithKline | Phase 3 | Recruiting | Pulmonary Disease, Chronic Obstructive | 981 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06959095) |
| March 19, 2025 | NCT06883305 | A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | AstraZeneca | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 990 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06883305) |
| March 14, 2025 | NCT06878261 | A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | AstraZeneca | Phase 3 | Recruiting | Chronic Obstructive Pulmonary Disease (COPD) | 990 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06878261) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 5 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 4 |
| [Haisco Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/haisco-pharmaceutical-group-co-ltd) | 3 |
| [Sanofi](https://specstream.ai/data/clinical-trials/company/sanofi) | 2 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| [Chia Tai Tianqing Pharmaceutical Group Co., Ltd.](https://specstream.ai/data/clinical-trials/company/chia-tai-tianqing-pharmaceutical-group-co-ltd) | 2 |
| [Boehringer Ingelheim](https://specstream.ai/data/clinical-trials/company/boehringer-ingelheim) | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| Fundación Instituto de Investigación Sanitaria de Navarra | 1 |
| Guy's and St Thomas' NHS Foundation Trust | 1 |
| Regend Therapeutics | 1 |
| Mahidol University | 1 |
| [Merck Sharp & Dohme LLC](https://specstream.ai/data/clinical-trials/company/merck-sharp-and-dohme-llc) | 1 |
| [Eurofarma Laboratorios S.A.](https://specstream.ai/data/clinical-trials/company/eurofarma-laboratorios-s-a) | 1 |
| JHSPH Center for Clinical Trials | 1 |
| University of Brawijaya | 1 |
| [Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sunshine-guojian-pharmaceutical-shanghai-co-ltd) | 1 |
| [Grifols Therapeutics LLC](https://specstream.ai/data/clinical-trials/company/grifols-therapeutics-llc) | 1 |
| Johns Hopkins University | 1 |
| Joincare Pharmaceutical Group Industry Co., Ltd | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 16 |
| China | 13 |
| Argentina | 8 |
| Germany | 8 |
| France | 8 |
| United Kingdom | 7 |
| Denmark | 7 |
| Poland | 7 |
| Spain | 7 |
| Italy | 6 |
| Japan | 6 |
| Brazil | 6 |
| Canada | 6 |
| Chile | 6 |
| Australia | 5 |
| Greece | 5 |
| Romania | 5 |
| South Korea | 5 |
| Hungary | 5 |
| Netherlands | 5 |
| Sweden | 5 |
| Bulgaria | 4 |
| Czechia | 4 |
| Israel | 4 |
| New Zealand | 4 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Farming services in the United States](https://specstream.ai/data/businesses/farming-services/united-states)
- [Office supply stores in the United States](https://specstream.ai/data/businesses/office-supply-stores/united-states)
- [Ultrasound imaging clinics in the United States](https://specstream.ai/data/businesses/ultrasound-imaging-clinics/united-states)
- [Collection agencies in the United States](https://specstream.ai/data/businesses/collection-agencies/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Restaurant wholesale companies in the United States](https://specstream.ai/data/businesses/restaurant-wholesale-companies/united-states)
